Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b study of pegylated liposomal doxorubicin plus pembrolizumab in hormone therapy-resistant metastatic breast cancer
MOH_2018-03-25_002278Phase 2Recruiting
- Sponsor
- פרופ' אלברטו גביזון
- Start
- Mar 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab and pegylated liposomal doxorubicin in breast cancer (2 cohorts), sponsored by פרופ' אלברטו גביזון. Primary endpoint: Safety of the combination. Started Mar 2018; status: recruiting.
02
Drugs
pembrolizumabpegylated liposomal doxorubicin
03
Conditions
breast cancer
Beyond the preview
Go deeper on MOH_2018-03-25_002278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-03-25_002278.